Ubrogepant Taken Early in a Migraine Attack, Before the Headache Starts
Observes how ubrogepant works when taken in the early warning phase of migraine.
Plain-language title generated from the registry record
Registry title: Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Key facts
- Where
- Aliso Viejo, Grand Island, and Naperville, United StatesSee the 3 sites
Where in United States
- Neurology and Pain Specialty Center /ID# 278508Aliso Viejo, United StatesTaking people
- Tri City Research Center, LLC /ID# 278800Grand Island, United StatesTaking people
- Chicago Headache Center & Research Inst /ID# 272345Naperville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT07310290
- Record updated
- 10 February 2026
- Original description
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks.Read full original descriptionShow less
PHASES: Prodrome in tHe reAl World: aSsESsing Ubrogepant Acute Use
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks.
Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US.
Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Inclusion: History of 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1; --a. Participants with a diagnosis of chronic migraine who report having 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1 due to concomitant preventive treatment are allowed in the study; Participant is currently prescribed ubrogepant and has been using ubrogepant for at least 3 months for the acute treatment of migraine in adults, according to the US Food and Drug Administration (FDA)-approved indication; Adult participants with current clinical diagnosis of migraine or chronic migraine according to International Classification of Headache Disorders (ICHD)-3.
Exclusion: Currently participating in a concurrent clinical or non-interventional study; Concomitant use with a strong Cytochrome P450 3A4 (CYP3A4 ) inhibitor; Current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus or painful cranial neuropathy as defined by ICHD-3.